AITRICS, a Seoul, South Korea–based AI technology company, has secured 35 billion won ($23.7M) in Series C funding, bringing its total raised to 73.1 billion won.
Investors
Nine Korean and international venture capital firms and financial institutions participated in the round, including Premier Partners, Hanriver Partners, Mirae Asset Venture Investment, Shinhan Investment-BSK Investment, KB Securities-Solidus Investment, SV Investment, and Mirae Asset Capital.
AITRICS Use of Funds
The company will use the funds to enhance flagship products AITRICS-VC and V.Doc Pro AI, support research and development (R&D) for new pipelines, and expand overseas operations in Asia and North America.
About AITRICS
AITRICS is a medical AI company that develops solutions for clinical decision support and patient care optimization. Its flagship products, AITRICS-VC (VitalCare) and V.Doc Pro, leverage predictive analytics to support clinicians, improve patient outcomes, and enhance operational efficiency. Founded in 2017, the company has established subsidiaries in Japan and the U.S.
Funding Details
Company: AITRICS
Raised: $23.7M
Round: Series C
Funding Date: November 2025
Investors: Premier Partners, Hanriver Partners, Mirae Asset Venture Investment, Shinhan Investment-BSK Investment, KB Securities-Solidus Investment, SV Investment, Mirae Asset Capital
Company Website: https://aitrics.com/kr/
Software Category: Medical AI / Healthcare AI
Source: https://aitrics.com/en/sub/media/news.php